Medpace Holdings, Inc. (MEDP) Stock Analysis
Healthcare · Diagnostics & Research
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV... Read more
TrendMatrix rates Medpace Holdings, Inc. (MEDP) as Buy (Wait for Entry) with high confidence. The stock trades at $466.80 with +1.5% upside to the $473.63 price target. Overall score: 6.2/10 across 10 analysis dimensions. Reward/risk ratio: 0.2:1.
Passes 3/4 gates (positive momentum, clean insider activity, no SEC red flags). Fails on favorable risk/reward ratio. Suitability: aggressive.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates Medpace Holdings, Inc. (MEDP) as Buy (Wait for Entry) with high confidence. Score 6.2/10. Entry target: $444.49.
Take-profit target: $473.63 (+1.5% upside). Reward/risk ratio: 0.2:1. Stop-loss: $422.70.
Analyst target reached - limited upside remaining; Expensive valuation; Below 200-day MA.
Medpace Holdings, Inc. trades at a P/E of 30.3 (forward 24.1). TrendMatrix value score: 4.0/10. Verdict: Buy (Wait for Entry).
19 analysts cover MEDP with a consensus score of 3.5/5. Average price target: $490.
What does Medpace Holdings, Inc. do?Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America,...
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.